Latest news

• Roche’s Evrysdi improves survival rates for infants with SMA

  FIREFISH evaluated the efficacy and safety of Evrysdi (risdiplam) in infants aged 1-7 months at the time of enrolment with type 1 spinal muscular atrophy (SMA).

• FDA grants priority review for Roche’s Evrysdi for spinal muscular atrophy in babies

  Evrysdi (risdiplam) is a drug designed to treat SMA through an increased and sustained production of the SMN protein – a vital protein for maintaining functioning motor neurons and movement – found throughout

• UK’s NICE recommends Roche’s Evrysdi

  deal. The National Institute for Health and Care Excellence (NICE) has recommended that Roche’s Evrysdi (risdiplam) be made available to patients in England as part of a managed access agreement.

• EU authorises Roche’s spinal muscular atrophy treatment Evrysdi

  The EC has approved Evrysdi (risdiplam) for the treatment of SMA in patients aged two months or older who have a clinical diagnosis of SMA type 1, type 2, type 3

• Biogen advances Spinraza study in SMA patients treated with Novartis’ Zolgensma

  Another competitor in the SMA market – Roche’s Evrysdi (risdiplam) – was recently approved in the US for the treatment of SMA in adults and children aged two months and older, following